Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis

Li, Debang; Si, Xiaoying; Wang, Shijie; Zhou, Yanming

doi:10.1016/j.hbpd.2018.10.001

Cited by 14 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even in 1:1 matched cohort with HCC, cHCC-CC still had poor prognosis than HCC either in LN negative (median overall survival time, cHCC-CC vs. HCC, 22.1 months vs. 66.6 months, p<0.001) or LN positive patients (median overall survival time, cHCC-CC vs. HCC, 11.1 months vs. 18.7 months, p=0.937) (Figure 3a, 3b). Previous study found the incidence of lymph node metastasis in cHCC-CC was about 8.3%-60.0% [6,13,14,25], with an average rate of 48% [26]. In further, cHCC-CC patients with positive LN infiltration suffered an unfavorable average overall survival time of 7.8 months than those of 20.2 months in negative LN [13].…”

Section: Discussionmentioning

confidence: 89%

“…Another population-based study suggested that lymph node status of cHCC-CC were strongly associated with overall survival, with a remarkable increased risk of death in positive LN patients [15]. A recent systematic review of cHCC-CC revealed that LN metastasis was strongly associated with decreased overall survival after surgical resection, with a hazards ratio of 2.84, p<0.0001 [26]. As LN metastasis resulted in worse prognosis than negative LN and lymphadenectomy was only performed in about one third of cHCC-CC patient [15], lymphadenectomy should be regarded as a routine procedure for suspected cHCC-CC following curative surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis

Tang¹,

Wang²,

Teng³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Clinical characteristics and prognosis among combined hepatocellular carcinoma (HCC) and cholangiocarcinoma (cHCC-CC) with HCC and intrahepatic cholangiocarcinoma (ICC) were inconsistent in previous studies. The aim of this study was to compare postoperative prognosis among cHCC-CC, HCC and ICC, and investigated the prognostic risk factor of cHCC-CC after surgical resection. Methods: A total of 1041 eligible patients with pathological diagnosis of cHCC-CC (n=135), HCC (n=698) and ICC (n=208) were enrolled in this study. Univariate and multivariate Cox analysis were applied for assessing important risk factors. cHCC-CC were further 1:1 matched with HCC and ICC on important clinical risk factors. Survival curves of matched and unmatched cohorts were depicted by Kaplan-Meier method with log-rank test. Results: Patients with cHCC-CC had similar rate of sex, age and cirrhosis with HCC (p<0.05) and comparable incidence of hepatitis B or C with ICC (p=0.197). Patients of cHCC-CC had intermediate prognosis between HCC and ICC, with median overall survival (OS) time of cHCC-CC, HCC and ICC of 20.5 months, 35.7 months and 11.6 months (p<0.001). In matched cohorts, the OS of cHCC-CC were worse than HCC (p<0.001) but comparable with ICC (p=0.06), while the disease-free survival (DFS) of cHCC-CC was worse than HCC but better than ICC (p<0.05). And lymph node infiltration and postoperative transarterial chemoembolization (TACE) were independent risk factors of cHCC-CC associated with prognosis. Conclusion: The long term survival of cHCC-CC was worse than HCC but comparable with ICC when matched on albumin level, tumor size, lymph node infiltration, tumor stage and margin. Presence of lymph node infiltration and no postoperative TACE were associated with poor prognosis of cHCC-CC.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis

Tang¹,

Wang²,

Teng³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…For HCC patients, increasing importance has been attached to liver transplantation (LT) thanks to the advances in surgical techniques and immunosuppression regimens, resulting in the mean 1-year and 5-year survival rates of 85-90% and 70-75%, respectively [13][14][15][16][17][18]. However, about 16% HCC patients develop recurrence after LT [19][20][21][22][23][24][25][26]; besides, ICIs can activate the alloreactive T cells and give rise to acute rejection and graft loss, but its safety and efficacy for HCC patients undergoing LT remain a source of controversy. This paper aimed to review the ICIs-related graft rejection following LT from various aspects.…”

Section: Introductionmentioning

confidence: 99%

Liver graft rejection following immune checkpoint inhibitors treatment: a review

Yang

Sang

2019

Med Oncol

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in a variety of solid tumors; nonetheless, they have not been well investigated and are still recognized as a relative contraindication for patients with a liver transplantation (LT) history, since ICIs treatment might potentially lead to graft rejection. The program death-1 (PD-1) and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways are implicated in the tolerance of transplanted organ, as well as blockade of the pathways, which contribute to eliminating tumors and may inadvertently lead to peripheral transplant rejection. Currently, no guidelines are available regarding the treatment for ICIs patients with a prior LT history. Therefore, this study was carried out to review the recent studies, attempting to introduce the ICIs-related graft rejection after LT from various aspects. We believed that ICIs could be given for the well-informed patients receiving LT and developed recurrence in a controlled setting. Typically, these patients should be treated according to a clinical care path or a prospective clinical trial, so as obtain a persistent anti-tumor immune response in the meantime of avoiding graft rejection, adjust the immunosuppression, reduce the possibility of graft loss following rejection, and have the opportunity to develop biomarkers for tumor response and transplant rejection.

show abstract

“…Lastly, a meta-analysis and systematic review of the largest set off pooled data available was recently published by Li et al, comparing patients who underwent liver resection and 301 patients who were transplanted. The authors confirmed no significant differences in overall survival and tumour recurrence between the two interventions [56].…”

Section: Transplantationmentioning

confidence: 74%

Treatment of Combined Hepatocellular and Cholangiocarcinoma

Leoni

Sansone

Lorenzo

et al. 2020

Cancers

View full text Add to dashboard Cite

Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary liver cancer. It is constituted by neoplastic cells of both hepatocellular and cholangiocellular derivation. Different histology types of HCC-CC have been reported, hinting at heterogeneous carcinogenic pathways leading to the development of this cancer. Due to its rarity and complexity, mixed HCC-CC is a scantly investigated condition with unmet needs and unsatisfactory outcomes. Surgery remains the preferred treatment in resectable patients. The risk of recurrence, however, is high, especially in comparison with other primary liver cancers such as hepatocellular carcinoma. In unresectable or recurring patients, the therapeutic options are challenging due to the dual nature of the neoplastic cells. Consequently, the odds of survival of patients with HCC-CC remains poor. We analysed the literature systematically about the treatment of mixed HCC-CC, reviewing the main therapeutic options and their outcomes and analysing the most interesting developments in this topic with a focus on new potential therapeutic avenues.

show abstract

Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis

Cited by 14 publications

References 43 publications

The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis

The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis

Liver graft rejection following immune checkpoint inhibitors treatment: a review

Treatment of Combined Hepatocellular and Cholangiocarcinoma

Contact Info

Product

Resources

About